NCT06479356View on ClinicalTrials.gov

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2026

Conditions
Non-Hodgkin LymphomaLarge B-cell Lymphoma
Interventions
BIOLOGICAL

Relma-cel

Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells

Trial Locations (1)

Unknown

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY